NASDAQ:AUTL
Autolus Therapeutics plc Stock News
$3.84
-0.0300 (-0.775%)
At Close: May 22, 2024
Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3
12:00pm, Monday, 24'th Feb 2020
LONDON, Feb. 24, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and AquaBounty Technologies (AQB)
12:15pm, Tuesday, 18'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ionis Pharmaceuticals (IONS) and Autolus Therapeutics (AUTL)
02:54pm, Friday, 31'st Jan 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS) and Autolus Therapeutics (AUTL). Ionis
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS – Research
Autolus Therapeutics (AUTL) Gets a Buy Rating from H.C. Wainwright
12:11pm, Friday, 31'st Jan 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Autolus Therapeutics (AUTL) today and set a price target of $24.00. The company's
Autolus Therapeutics (AUTL) Gets a Buy Rating from H.C. Wainwright
12:11pm, Friday, 31'st Jan 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a
Autolus Therapeutics plc (AUTL) today announced additional data regarding its ongoing Phase 1/2 clinical trial of its next-generation programmed T cell therapy, AUTO3, to treat adults with relapsed/
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
12:12pm, Tuesday, 28'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmace
Autolus Announces Closing of Public Offering
09:00pm, Monday, 27'th Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten
Autolus’ Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting
12:00pm, Monday, 27'th Jan 2020
LONDON, Jan. 27, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces.
Reviewing Autolus Therapeutics (NASDAQ:AUTL) & AIM ImmunoTech (NASDAQ:AIM)
06:52am, Saturday, 25'th Jan 2020
Autolus Therapeutics (NASDAQ:AUTL) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of t
Why Autolus Therapeutics Shares Are Plunging Today
04:44pm, Thursday, 23'rd Jan 2020
Investors are reacting negatively to the biotech's public stock offering.
Arix Bioscience Plc - Autolus announces pricing of public offering - Vox Markets
07:00am, Thursday, 23'rd Jan 2020
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014. LONDON, 23 January 2020: Arix Bioscience plc, a global venture capital company focused o
Autolus Announces Pricing of Public Offering
02:41am, Thursday, 23'rd Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in th
